Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Feb 24, 2026 1:00 PM - Feb 26, 2026 5:30 PM

(Central European Time)

Artificial Intelligence in Pharmacovigilance

A practical orientation virtual live training course for the next level of pharmacovigilance technology as it is being implemented across the industry.

Faculty

Andrew  Mitchell

Andrew Mitchell

CEO and Founder, YEZA.ai, United States

Andrew is the CEO/Founder of YEZA.ai, delivering AI-Agents for Safety Intake that's transforming Pharmacovigilance. He has consistently led at the forefront of innovation, having successfully delivered two next-gen Safety systems and holds 3 US-patents related to Clinical and PV technology. A 'no nonsense' reputation built on 25 years of experience in software design, development, strategy, implementation, marketing, and go-to-market activities. Extensive experience with Oracle Argus, ArisGlobal LSMV, Veeva Vault Safety and Medidata Rave.

Jan  Petracek, MD, MSc

Jan Petracek, MD, MSc

CEO, iVigee Services a.s., Czech Republic

Physician and pharmacovigilance leader with more than 26 years of experience as a senior regulator, QPPV, auditor, trainer, and serial entrepreneur. Working in intelligent automation in PV for over 10 years, with the last 4 years dedicated to hands-on development and implementation of generative AI and AI agents in PV operations, including the validation of such systems and their defence before auditors and inspectors. Faculty member of DIA’s AI in PV training course and lecturer at the European Course in Pharmaceutical Medicine. Fellow of the International Society of Pharmacovigilance. Educated at Charles University in Prague, Imperial College London, with additional executive education in business and agentic AI from Harvard and MIT.

Phil  Tregunno

Phil Tregunno

Deputy Director - Patient Safety Monitoring, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Phil is the Deputy Director of Patient Safety Monitoring within MHRA’s Safety & Surveillance function and has over twenty years of experience working in pharmacovigilance. Prior to his current role Phil spent fourteen years leading and developing the pharmacovigilance system, including technology, processes, and relevant aspects of Pharmacovigilance Legislation. He is now accountable for Patient Safety Monitoring across medicines, vaccines, devices, defects and blood products. Phil was responsible delivery of MHRA systems for COVID-19 vaccine surveillance and their integration into the healthcare system. For several years he has led international projects to develop and deliver tools for global pharmacovigilance.

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.